TCRβ repertoire analysis in PBMCs by next generation sequencing. TCRβ repertoire before and after mogamulizumab treatment in patients with (n = 16) (A) or without (n = 8) (B) EM, and before and after chemotherapy without mogamulizumab (n = 11) (C). Bar graphs and pie charts in the left and right panels depict the TCRβ repertoire in PBMCs before and after treatment, respectively, in each patient. Each CDR3 sequence and its frequency is shown by individual color and height, respectively, in the bar graph. The blue and red lines on the right side indicate the CDR3 sequences specific to the samples obtained before and after treatment, respectively. The blue, red, and gray slices in the pie charts indicate the frequency of the CDR3 sequences specific to the samples obtained before and after treatment, as well as those detected at both points, respectively. The percentages of the CDR3 sequences specific to the samples obtained before and after treatment are shown as blue and red numbers, respectively, below the pie charts.